Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty

 
• By Eleanor Malone

Just weeks after Johnson & Johnson halted development of its BACE inhibitor for Alzheimer's and a few months after Merck & Co failed at Phase III, Lilly and AstraZeneca end trials of lanabecestat.

magnetic resonance image (MRI) of the brain human

More from Neurological

More from Therapy Areas